|
|
Substance Name: Ondansetron [USP:INN:BAN]
RN: 99614-02-5
UNII: 4AF302ESOS
InChIKey: FELGMEQIXOGIFQ-UHFFFAOYSA-N
Note
- A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Molecular Formula
- C18-H19-N3-O
Molecular Weight
- 293.3681
Classification Codes
- Anti-Anxiety Agents
- Antiemetics
- Antipruritics
- Antipsychotic Agents
- Autonomic Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Dermatologic Agents
- Drug / Therapeutic Agent
- Gastrointestinal Agents
- Human Data
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Antagonists
- Tranquilizing Agents
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Ondansetron
- Ondansetron [USP:INN:BAN]
MeSH Heading
- Ondansetron
Synonyms
- (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
- 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
- BRN 3622981
- GR 38032
- GR 38032X
- HSDB 8304
- Odansetron [common misspelling of ondansetron]
- Ondansetron
- Ondansetron Injection
- UNII-4AF302ESOS
- Zofran
- Zofran ODT
- Zophren
- Zudan
- Zuplenz
Systematic Name
- 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-
Registry Numbers
CAS Registry Number
- 99614-02-5
FDA UNII
- 4AF302ESOS
Other Registry Numbers
- 108303-49-7
- 116002-70-1
Related Registry Numbers
- 103639-04-9 (mono-hydrochloride dihydrate)
- 99614-01-4 (mono-hydrochloride)
System Generated Number
- 0099614025
Structure Descriptors
InChI
InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3InChIKey
FELGMEQIXOGIFQ-UHFFFAOYSA-NSmiles
Cc1nccn1CC2CCc3c(C2=O)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD | intravenous | > 10mg/kg (10mg/kg) | Seminars in Oncology. Vol. 19(Suppl, | |
man | TDLo | intravenous | 229ug/kg/I (0.229mg/kg) | LIVER: "JAUNDICE, OTHER OR UNCLASSIFIED" | Lancet. Vol. 344, Pg. 190, 1994. |
mouse | LD | intraperitoneal | > 5mg/kg (5mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 46, Pg. 401, 1996. | |
mouse | LD | oral | > 10mg/kg (10mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 46, Pg. 401, 1996. | |
mouse | LDLo | intravenous | 2500ug/kg (2.5mg/kg) | Seminars in Oncology. Vol. 19(Suppl, | |
rat | LDLo | intravenous | 20mg/kg (20mg/kg) | Seminars in Oncology. Vol. 19(Suppl, |